| Title |
First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, July 2013
|
| DOI | 10.1002/14651858.cd006407.pub2 |
| Pubmed ID | |
| Authors |
Frank Peinemann, Carmen Bartel, Ulrich Grouven |
| Abstract |
Acquired severe aplastic anemia is a rare and potentially fatal disease, which is characterized by hypocellular bone marrow and pancytopenia. The major signs and symptoms are severe infections, bleeding, and exhaustion. First-line allogeneic hematopoietic stem cell transplantation (HSCT) of a human leukocyte antigen (HLA)-matched sibling donor (MSD) is a treatment for newly diagnosed patients with severe aplastic anemia. First-line treatment with ciclosporin and/or antithymocyte or antilymphocyte globulin (as first-line immunosuppressive therapy) is an alternative to MSD-HSCT and is indicated for patients where no MSD is found. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 200 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 2 | 1% |
| Netherlands | 1 | <1% |
| South Africa | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 195 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 33 | 17% |
| Student > Bachelor | 29 | 14% |
| Researcher | 17 | 9% |
| Student > Postgraduate | 17 | 9% |
| Student > Ph. D. Student | 15 | 8% |
| Other | 37 | 19% |
| Unknown | 52 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 96 | 48% |
| Nursing and Health Professions | 13 | 7% |
| Psychology | 8 | 4% |
| Biochemistry, Genetics and Molecular Biology | 6 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 21 | 11% |
| Unknown | 51 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2019.
All research outputs
#6,927,055
of 22,715,151 outputs
Outputs from Cochrane database of systematic reviews
#8,557
of 12,313 outputs
Outputs of similar age
#59,793
of 197,838 outputs
Outputs of similar age from Cochrane database of systematic reviews
#165
of 240 outputs
Altmetric has tracked 22,715,151 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 12,313 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,838 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 240 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.